Diabetes, Glycated Hemoglobin ( HbA1c) , and Neuroaxonal Damage in Parkinson's Disease ( MARK‐PD Study )

Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease

(2021) Ioanna Markaki et al.   MOVEMENT DISORDERS

Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression

(2021) Harneek Chohan et al.   MOVEMENT DISORDERS

HbA1c and Motor Outcome in Parkinson's Disease in the Mark‐PD Study

(2021) Simone Zittel et al.   MOVEMENT DISORDERS

Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease

(2021) Whitley W. Aamodt et al.   MOVEMENT DISORDERS

Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD)

(2021) Louisa Niemann et al.   PARKINSONISM & RELATED DISORDERS

Parkinson disease-associated cognitive impairment

(2021) Dag Aarsland et al.   Nature Reviews Disease Primers

Parkinson's Disease and Type 2 Diabetes: HbA1c Is Associated with Motor and Cognitive Severity

(2021) Brook Huxford et al.   MOVEMENT DISORDERS

Subclinical Cardiac Microdamage, Motor Severity, and Cognition in Parkinson's Disease

(2020) Chi‐un Choe et al.   MOVEMENT DISORDERS

Insulin Sensitivity in De Novo Parkinson's Disease: A Hyperinsulinemic‐Euglycemic Clamp Study

(2020) N. Ahmad Aziz et al.   MOVEMENT DISORDERS

Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes

(2020) Ruth Brauer et al.   BRAIN

Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease

(2019) Dilan Athauda et al.   JAMA Neurology

Body mass index, diabetes, and the risk of Parkinson's disease

(2019) Su‐Min Jeong et al.   MOVEMENT DISORDERS

Diabetes mellitus and Parkinson disease

(2018) Gennaro Pagano et al.   NEUROLOGY

Association between diabetes and subsequent Parkinson disease

(2018) Eduardo De Pablo-Fernandez et al.   NEUROLOGY

Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)

(2018) Brit Mollenhauer et al.   MOVEMENT DISORDERS

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

(2017) Dilan Athauda et al.   LANCET

Insulin resistance and Parkinson’s disease: A new target for disease modification?

(2016) D. Athauda et al.   PROGRESS IN NEUROBIOLOGY

Diabetes and Risk of Parkinson's Disease: A systematic review and meta-analysis

(2011) E. Cereda et al.   DIABETES CARE